The restricted expression of sclerostin in bone and the lack of complications in organs other than the skeleton in humans and animals with sclerostin deficiency made this protein an attractive target for the development of a novel anabolic therapy for osteoporosis. This evidence concerns the gene SOST and osteoporosis.